EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis

Vinita Chaturvedi, Namrata Dwivedi, Rama P Tripathi, Sudhir Sinha

The Journal of General and Applied Microbiology · 2007 · 53 (6) · 333-337

DOI: 10.2323/jgam.53.333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of General and Applied Microbiology, 2007. Verfasst von Vinita Chaturvedi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India. vinita_chaturvedi@cdri.res.in. Hauptthemen laut MEDLINE: Mycobacterium smegmatis. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New and better drugs are needed for tuberculosis (TB), particularly for the multi-drug resistant (MDR) disease. However, the highly infectious nature of MDR Mycobacterium tuberculosis restricts its use for large scale screening of probable drug candidates. We have evaluated the potential of a screen based on a 'fast grower' mycobacterium to shortlist compounds which could be active against MDR M. tuberculosis. Sensitivity profiles of M. smegmatis, M. phlei and M. fortuitum as well as MDR clinical isolates of M. tuberculosis were determined against anti-TB drugs isoniazid and rifampicin. Among the three fast growers, M. smegmatis was found to display a profile similar to MDR M. tuberculosis. Subsequently we evaluated the performance of M. smegmatis as a 'surrogate' screen for 120 compounds which were synthesized for anti-TB activity. Fifty of these molecules were active against M. tuberculosis H(37)Rv at a minimum inhibitory concentration (MIC) cutoff of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium smegmatisAntitubercular AgentsBiomarkersDrug Resistance, BacterialDrug Resistance, Multiple, BacterialIsoniazidMicrobial Sensitivity TestsMycobacterium tuberculosisRifampinSensitivity and Specificity

Substanzen

Antitubercular AgentsBiomarkersIsoniazidRifampin

Autor:innen und Institutionen

  • Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India. vinita_chaturvedi@cdri.res.in

Zitieren

APA

Chaturvedi, V., Dwivedi, N., Tripathi, R. P., & Sinha, S. (2007). Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. The Journal of General and Applied Microbiology, 53(6), 333-337. https://doi.org/10.2323/jgam.53.333

Vancouver

Chaturvedi V, Dwivedi N, Tripathi RP, Sinha S. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. The Journal of General and Applied Microbiology. 2007;53(6):333-337. doi:10.2323/jgam.53.333

BibTeX
@article{Chaturvedi2007,
  author = {Chaturvedi, Vinita and Dwivedi, Namrata and Tripathi, Rama P and Sinha, Sudhir},
  title = {Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis},
  journal = {The Journal of General and Applied Microbiology},
  year = {2007},
  volume = {53},
  number = {6},
  pages = {333--337},
  doi = {10.2323/jgam.53.333}
}
Kostenlos starten →